Yuji Makita

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The role of invariant natural killer T (iNKT) cells in antitumor immunity has been studied extensively, and clinical trials in patients with advanced cancer have revealed a prolonged survival in some cases. In recent years, humanized blocking antibodies against co-stimulatory molecules such as PD-1 have been developed. The enhancement of T cell function is(More)
  • 1